SCHEMBL11248434

SCHEMBL11248434

CC(=O)c1ccc([N+](=O)[O-])c(F)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.56
TDP1 Q9NUW8 1/20 0.56
MAPK1 P28482 1/20 0.52
PDE7A Q13946 1/20 0.51
MAPT P10636 2/20 0.50
ALDH1A1 P00352 1/20 0.50
TSHR P16473 2/20 0.49
CASP6 P55212 1/20 0.49
KMT2A Q03164 2/20 0.48
POLB P06746 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
AKR1C3 P42330 1/20 0.46
AKR1C2 P52895 1/20 0.46
SLC6A5 Q9Y345 2/20 0.45
CTSK P43235 1/20 0.45
TTR P02766 1/20 0.45
MEN1 O00255 1/20 0.45
SLC6A9 P48067 1/20 0.44
ITGB1 P05556 1/20 0.44
ITGA5 P08648 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16956237 0.87 ATM (0.58) ATMTDP1MAPK1PDE7AMAPT
SCHEMBL29721575 0.86 ITGB1 (0.57) MAPK1PDE7AMAPTALDH1A1TSHR
SCHEMBL9157 0.86 ITGB1 (0.57) MAPK1PDE7AMAPTALDH1A1TSHR
SCHEMBL22638286 0.84 ATM (0.55) ATMTDP1MAPK1PDE7AALDH1A1
SCHEMBL29446911 0.84 ATM (0.55) ATMTDP1MAPK1PDE7AALDH1A1
SCHEMBL6238 0.84 CASP6 (0.70) ATMTDP1TSHRCASP6KMT2A
SCHEMBL30001328 0.84 CASP6 (0.70) ATMTDP1TSHRCASP6KMT2A
SCHEMBL11690925 0.83 CASP6 (0.69) ATMMAPK1PDE7AMAPTALDH1A1
Acetic Acid SCHEMBL28375520 0.83 MAPT (0.55) MAPK1PDE7AMAPTALDH1A1TSHR
Hydrochloric Acid SCHEMBL5568198 0.82 CASP6 (0.68) ATMTDP1TSHRCASP6KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138977-A1 MODULATORS OF BETA CATENIN AND USES THEREOF DEWPOINT THERAPEUTICS INC (US) 2026-05-21 US disclosed
US-12612396-B1 Modulators of beta catenin and uses thereof DEWPOINT THERAPEUTICS, INC. (US) 2026-04-28 US disclosed
US-20260015352-A1 METHYLTRANSFERASE INHIBITOR AND USE THEREOF CYTOSINLAB THERAPEUTICS CO LTD (CN) 2026-01-15 US disclosed
WO-2025201532-A1 NOVEL PEGYLATION COMPOUNDS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF NUPHASE THERAPEUTICS (SHANGHAI) LIMITED., CO. (CN) 2025-10-02 WO disclosed
WO-2025201533-A1 NOVEL ACIDIC COMPOUNDS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF NUPHASE THERAPEUTICS (SHANGHAI) LIMITED., CO. (CN) 2025-10-02 WO disclosed
EP-4598933-A1 PHOSPHORAMIDATE COMPOUNDS AND USES THEREOF Allorion Therapeutics Inc (US) 2025-08-13 EP disclosed
CN-119968377-A Phosphoramidate compounds and uses thereof 安锐生物医药公司 2025-05-09 CN disclosed
WO-2024208228-A1 NOVEL COMPOUNDS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF NUPHASE THERAPEUTICS (HANGZHOU) LIMITED., CO. (CN) 2024-10-10 WO disclosed
WO-2024175999-A2 BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF DUNAD THERAPEUTICS LTD. (GB) 2024-08-29 WO disclosed
WO-2024078392-A1 PHOSPHORAMIDATE COMPOUNDS AND USES THEREOF ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) 2024-04-18 WO disclosed
US-20170174704-A1 QUINOXALINE COMPOUNDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2017-06-22 US disclosed
US-20150320758-A1 SELECTIVE INHIBITORS OF HISTONE DEACTYLASE PHARMACYCLICS LLC 2015-11-12 US disclosed
US-8906954-B2 Selective inhibitors of histone deacetylase PHARMACYCLICS, INC. (US) 2014-12-09 US disclosed
US-8846655-B2 4-substituted-2-phenoxy-phenylamine delta opioid receptor modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-09-30 US disclosed
US-8466193-B2 Selective inhibitors of histone deacetylase PHARMACYCLICS, INC. (US) 2013-06-18 US disclosed
US-8440662-B2 Substituted quinazoline and pyrido-pyrimidine derivatives ENDO PHARMACEUTICALS, INC. (US) 2013-05-14 US disclosed
US-20120302541-A1 4-SUBSTITUTED-2-PHENOXY-PHENYLAMINE DELTA OPIOID RECEPTOR MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2012-11-29 US disclosed
US-20110269759-A1 PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2011-11-03 US disclosed
US-20110081409-A1 SELECTIVE INHIBITORS OF HISTONE DEACETYLASE PHARMACYCLICS LLC 2011-04-07 US disclosed
US-4315009-A Antisecretory guanidine derivatives and pharmaceutical compositions containing them IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1982-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302541-A1 4-SUBSTITUTED-2-PHENOXY-PHENYLAMINE DELTA OPIOID RECEPTOR MODULATORS OPRK1, OPRD1, OPRM1 ATM 3796/4885TDP1 2913/4885MAPK1 1855/4885
US-12612396-B1 Modulators of beta catenin and uses thereof CTNNB1, CTNND1, CTNNA1 ATM 2327/4885TDP1 861/4885MAPK1 3934/4885
US-20110081409-A1 SELECTIVE INHIBITORS OF HISTONE DEACETYLASE HDAC8, HDAC1, HDAC11 ATM 1815/4885TDP1 775/4885MAPK1 2557/4885
US-20170174704-A1 QUINOXALINE COMPOUNDS AND USES THEREOF NAMPT, NQO2, NNMT ATM 2524/4885TDP1 1943/4885MAPK1 2199/4885
US-20260138977-A1 MODULATORS OF BETA CATENIN AND USES THEREOF CTNNB1, CTNND1, CTNNA1 ATM 2327/4885TDP1 861/4885MAPK1 3934/4885
US-20110269759-A1 PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS OPRD1, OPRK1, OPRM1 ATM 3127/4885TDP1 761/4885MAPK1 2621/4885
US-20260015352-A1 METHYLTRANSFERASE INHIBITOR AND USE THEREOF EZH2, DOT1L, EHMT1 ATM 3408/4885TDP1 2176/4885MAPK1 1297/4885
US-20150320758-A1 SELECTIVE INHIBITORS OF HISTONE DEACTYLASE HDAC8, HDAC1, HDAC5 ATM 2214/4885TDP1 493/4885MAPK1 3103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.